دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
A New Dancing Partner for Venetoclax: Gilteritinib.
Fathi, Amir T. MD 1,,
doi : 10.1200/JCO.22.01386
Volume 40(35) pgs. 4033-4160 December 10, 2022
In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer.
Davidson, Nancy E. MD 1,
doi : 10.1200/JCO.22.01465
Who Should Have Multigene Germline Testing for Hereditary Cancer?.
Savage, Sharon A. MD 1,
doi : 10.1200/JCO.22.01691
You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer?.
Sobrero, Alberto F. MD 1,,; Pastorino, Alessandro MD 1,; Zalcberg, John R. MBBS, PhD 2,
doi : 10.1200/JCO.22.01531
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Daver, Naval MD 1,; Perl, Alexander E. MD 2,; Maly, Joseph MD 3; Levis, Mark MD, PhD 4,; Ritchie, Ellen MD 5,; Litzow, Mark MD 6,; McCloskey, James MD 7,; Smith, Catherine C. MD 8,; Schiller, Gary MD 9,; Bradley, Terrence MD 10,11,; Tiu, Ramon V. MD 12,; Naqvi, Kiran MD 13,; Dail, Monique PhD 13,; Brackman, Deanna PhD 14,; Siddani, Satya PhD 14,; Wang, Jing PhD 14,; Chyla, Brenda PhD 14,; Lee, Paul MD, PhD 14,; Altman, Jessica K. MD 15,,
doi : 10.1200/JCO.22.00602
The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut burden or induces sustained efficacy.
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
Merli, Michele MD 1; Rattotti, Sara MD 2; Spina, Michele MD 3,; Re, Francesca MD 4; Motta, Marina MD 5; Piazza, Francesco MD 6; Orsucci, Lorella MD 7; Ferreri, Andres J.M. MD 8,; Perbellini, Omar MD 9; Dodero, Anna MD 10; Vallisa, Daniele MD 11; Pulsoni, Alessandro MD 12,; Santoro, Armando MD 13,; Sacchi, Paolo MD 14; Zuccaro, Valentina MD 14; Chimienti, Emanuela MD 3; Russo, Filomena MD 4; Visco, Carlo MD 15,; Zignego, Anna Linda MD 16; Marcheselli, Luigi MSc 17,; Passamonti, Francesco MD 1,18,; Luminari, Stefano MD 19,20,; Paulli, Marco MD 21,22,; Bruno, Raffaele MD 14,23; Arcaini, Luca MD 2,22,,; on behalf of Fondazione Italiana Linfomi
doi : 10.1200/JCO.22.00668
We prospectively treated patients with hepatitis C virus (HCV)-associated indolent lymphomas with genotype-appropriate direct-acting antivirals (DAAs) with the aim to evaluate virologic and hematologic outcomes.
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
Johansson, Annelie MSc, PhD 1,; Dar, Huma MSc 1; van 't Veer, Laura J. MSc, PhD 2,; Tobin, Nicholas P. MSc, PhD 1,; Perez-Tenorio, Gizeh MSc, PhD 3; Nordenskjold, Anna MD, PhD 4; Johansson, Ulla MD 5; Hartman, Johan MD, PhD 1,; Skoog, Lambert MD 1; Yau, Christina PhD 6,7; Benz, Christopher C. MD 6,8,; Esserman, Laura J. MD 7,; Stal, Olle MSc, PhD 3; Nordenskjold, Bo MD, PhD 3; Fornander, Tommy MD, PhD 1,; Lindstrom, Linda S. MSc, PhD 1
doi : 10.1200/JCO.21.02844
To assess the long-term (20-year) endocrine therapy benefit in premenopausal patients with breast cancer. METHODS: Secondary analysis of the Stockholm trial (STO-5, 1990-1997) randomly assigning 924 premenopausal patients to 2 years of goserelin (3.6 mg subcutaneously once every 28 days), tamoxifen (40 mg orally once daily), combined goserelin and tamoxifen, or no adjuvant endocrine therapy (control) is performed.
Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment.
Yurgelun, Matthew B. MD 1,2,3,; Uno, Hajime PhD 1,2,; Furniss, C. Sloane PhD 1,; Ukaegbu, Chinedu MBBS, MPH 1; Horiguchi, Miki PhD 1,2; Yussuf, Amal BS 4,; LaDuca, Holly MS 4,; Chittenden, Anu MS 1,; Garber, Judy E. MD, MPH 1,2,3,; Syngal, Sapna MD, MPH 1,2,3,,
doi : 10.1200/JCO.22.00120
With the availability of multigene panel testing (MGPT) for hereditary cancer risk assessment, clinicians need to assess the likelihood of pathogenic germline variants (PGVs) across numerous genes in parallel.
Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
Michaeli, Daniel Tobias MS 1,2,3,; Michaeli, Thomas MS 1,2,3,4
doi : 10.1200/JCO.22.00535
Clinical trial evidence is routinely evaluated for initial drug approvals, yet the benefit of indication extensions remains uncertain. This study evaluates the clinical benefit supporting new cancer drugs' initial and supplemental US Food and Drug Administration (FDA) indication approval.
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
Desai, Ami V. MD, MSCE 1,; Gilman, Andrew L. MD 2; Ozkaynak, Mehmet Fevzi MD 3; Naranjo, Arlene PhD 4,; London, Wendy B. PhD 5,; Tenney, Sheena C. MSPH 4; Diccianni, Mitchell PhD 6; Hank, Jacquelyn A. PhD 7; Parisi, Marguerite T. MD, MS 8; Shulkin, Barry L. MD, MBA 9,; Smith, Malcolm MD, PhD 10; Moscow, Jeffrey A. MD 11; Shimada, Hiroyuki MD 12; Matthay, Katherine K. MD 13,; Cohn, Susan L. MD 1,; Maris, John M. MD 14,; Bagatell, Rochelle MD 14,; Sondel, Paul M. MD, PhD 7,; Park, Julie R. MD 8; Yu, Alice L. MD, PhD 6,15,,
doi : 10.1200/JCO.21.02478
Postconsolidation immunotherapy including dinutuximab, granulocyte-macrophage colony-stimulating factor, and interleukin-2 improved outcomes for patients with high-risk neuroblastoma enrolled on the randomized portion of Children's Oncology Group study ANBL0032.
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212: NRG Oncology Study.
Copeland, Larry J. MD 1,,; Brady, Mark F. PhD 2,; Burger, Robert A. MD 3,; Rodgers, William H. MD 4; Huang, Helen Q. MS 2; Cella, David PhD 5,; O'Malley, David M. MD 1,; Street, Daron G. MD 6,; Tewari, Krishnansu S. MD 7,; Bender, David P. MD 8; Morris, Robert T. MD 9,; Lowery, William J. MD 10,; Miller, David S. MD 11,; Dewdney, Summer B. MD 12; Spirtos, Nick M. MD 13; Lele, Shashikant B. MD 14; Guntupalli, Saketh MD 15,; Ueland, Frederick R. MD 16; Glaser, Gretchen E. MD 17; Mannel, Robert S. MD 6,; DiSaia, Philip J. MD 7,+
doi : 10.1200/JCO.22.00146
To compare taxane maintenance chemotherapy, paclitaxel (P) and paclitaxel poliglumex (PP), with surveillance (S) in women with ovarian, peritoneal, or fallopian tube (O/PC/FT) cancer who attained clinical complete response after first-line platinum-taxane therapy.
Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.
Frey, Melissa K. MD, MS 1,; Ahsan, Muhammad Danyal 1; Bergeron, Hannah BA 1; Lin, Jenny BA 1; Li, Xuan MD 1; Fowlkes, Rana K. MD 1; Narayan, Priyanka BA 1; Nitecki, Roni MD 2; Rauh-Hain, Jose Alejandro MD 2,; Moss, Haley A. MD, MPH 3; Baltich Nelson, Becky MS 1; Thomas, Charlene MS 1,; Christos, Paul J. PhD, MS 1; Hamilton, Jada G. PhD, MPH 4; Chapman-Davis, Eloise MD 1; Cantillo, Evelyn MD 1; Holcomb, Kevin MD 1,; Kurian, Allison W. MD, MSc 5,; Lipkin, Steven MD, PhD 1; Offit, Kenneth MD, MPH 4,; Sharaf, Ravi N. MD, MS 1
doi : 10.1200/JCO.22.00303
Evidence-based guidelines recommend cascade genetic counseling and testing for hereditary cancer syndromes, providing relatives the opportunity for early detection and prevention of cancer.
Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology.
Herbst, Roy S. MD, PhD 1,,; Hatsukami, Dorothy PhD 2,; Acton, Dana JD 3; Giuliani, Meredith MBBS, MEd, PhD 4,; Moushey, Allyn MSW 5; Phillips, Jonathan MPH 5; Sherwood, Shimere PhD 5; Toll, Benjamin A. PhD 6,; Viswanath, Kasisomayajula PhD 7; Warren, Nicholas J.H. PhD 3; Warren, Graham W. MD, PhD 6,; Alberg, Anthony J. PhD, MPH 8
doi : 10.1200/JCO.22.01749
AB Combustible tobacco use has reached historic lows, demonstrating the importance of proven strategies to reduce smoking since publication of the 1964 Surgeon General's report. In contrast, the use of electronic nicotine delivery systems (ENDS), specifically e-cigarettes, has grown to alarming rates and threatens to hinder progress against tobacco use.
Could Some Reports of Trastuzumab Cardiotoxicity Be a Surveillance Artifact?.
Ewer, Michael S. MD, JD, PhD; Swain, Sandra M. MD
doi : 10.1200/JCO.22.01006
Reply to M.S. Ewer et al.
Greenlee, Heather PhD; Rillamas-Sun, Eileen PhD, MPH; Cheng, Richard MD, MSc; Iribarren, Carlos MD, MPH, PhD; Rana, Jamal S. MD, PhD; Nguyen-Huynh, Mai MD, MAS; Kushi, Lawrence H. ScD; Kwan, Marilyn L. PhD
doi : 10.1200/JCO.22.01353
